Optometry practices are being urged to review their payroll tax obligations and business structures following a court ruling that could put some healthcare businesses in breach of tax laws. Read more
Australian biotech raises an additional $50 million for AMD drug
Melbourne-based biotech company Opthea has announced it has secured commitments from both Australian and international investors for an additional $50 million to put towards the development of its treatment for neovascular age-related macular degeneration (AMD). Read more
Hoya secures ‘VIP status’ for Australian border checks
Australian border officials have granted Hoya Lens Australia a special status that will reduce red tape and smooth the supply of its products into and out of the country. Read more
CooperVision’s MiSight receives FDA approval, to launch in 2020
CooperVision has received clearance from the US Food and Drug Administration (FDA) for its MiSight 1 Day Contact Lens for Childhood Myopia. Read more
ODMA unveils latest board appointees for upcoming term
Essilor’s new Australasian head Mr Pierre Longerna has joined the Optical Distributors and Manufacturers Association (ODMA) as a director, while Mr Robert Sparkes returns for a third term as chairman. Read more
Internationally recognised optometrist joins George & Matilda
Gerry & Johnson Optometrists, owned and operated by renowned Australian clinical optometrist and researcher Dr Kate Gifford, is the latest high-profile practice to join George & Matilda Eyecare (GME). Read more
Zeiss gifts ‘gold standard’ optical biometry device to Indigenous eye clinic
Carl Zeiss Meditec has donated its latest generation optical biometry device to the Indigenous Diabetes Eyes and Screening (IDEAS) Van. Read more
New Specsavers report shows impact of eye health strategies
Specsavers’ latest snapshot into Australian eye health has revealed referrals for eye disease are soaring to unprecedented levels thanks to the systematic use of imaging technology and ophthalmology-led education, as well as other clinical interventions. Read more
Biogen unveils plan to commercialise Eylea and Lucentis generics
Multinational biotech company Biogen has proposed a deal worth up to US$310 million (AU$453 m) to supply biosimilar treatments of Lucentis and Eylea to major global markets, including Australia. Read more
George & Matilda recognised for outstanding growth
For the second year in a row George & Matilda Eyecare has been recognised with top honours at the Australian Growth Company Awards. Read more